| Sumario: | The primary goal of diabetes management is to help patients achieve near-normal glycaemia as safely as possible to minimise complications, with research supporting early, intensive glycaemic control for long-term benefits. Hybrid closed-loop (HCL) systems, combining insulin pumps and continuous glucose monitors, use algorithms to automatically adjust insulin delivery in response to glucose levels, promoting improved glycaemic control. HCL therapy is currently the most effective treatment for type 1 diabetes in children and young people (CYP), as evidenced by lower mean HbA1c levels in those using HCL compared to other treatment. Therefore, Hillingdon Hospital's Paediatric Diabetes Team introduced HCL therapy as standard care for new diagnoses. This article reports on its approach to initiating HCL insulin therapy at diagnosis for all paediatric patients with type 1 diabetes. The team presents its experience, including practical implications, clinical outcomes, patient satisfaction and healthcare professional experience, to support the introduction of this practice across other paediatric diabetes services.
|
|---|